![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_122,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Retinal Vasculitis in Intermediate Uveitis: A Hidden Driver of Uveitis Flares and Decreased Remission Rate
Presenter:
Andrew Briere DO
Authors:
Andrew Briere DO (1,2), Andrew Gregory MD (1,2), Yasmin Massoudi BS (1,2), Parvin Aghayeva MD (1,2), Yu Su OD (1,2), Amanda Patti BS (1,2), William Thorley BS (1,2), Steohen D. Anesi MD (1,2), Peter Y. Chang MD (1,2)
1The Ocular Immunology and Uveitis Foundation, Waltham, MA, 1440 Main St #201, Waltham, MA, 02451
2Massachusetts Eye Research and Surgery Institution, Waltham, MA, 1440 Main St #201, Waltham, MA, 02451
Affiliation:
Purpose: To investigate the effect of retinal vasculitis (RV) in patients with intermediate uveitis (IU) on uveitis flares (UFs) and indices related to remissions from UF
Methods: A retrospective analysis of patients with IU with and without RV was conducted from a single tertiary care center specializing in the treatment of ocular inflammatory disease
Results: A total of 175 patients were included in the study, with 72 and 103 patients having and not having concurrent RV, respectively. In IU patients, RV was associated with an increased risk of uveitis flares (UFs) in the first 2 years after diagnosis, a shorter period of remission from UFs, and lower rates of achieving durable remission (≥ 2 years of not having a UF following the cessation of immunosuppressive medications) (P-values < 0.05). These risks remained significant even after adjusting for certain demographic factors, such as age at IU diagnosis, female sex, and visual acuity. Additionally, when considering the severity of RV and laterality, diffuse RV and bilateral RV showed similar associations to UFs and remission from flares.
Conclusion:In IU patients, RV is linked to more frequent UFs and short remission from UFs, which underscores the need for close monitoring and personalized therapy for patients in this high-risk population.